Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. develops investigational biologics intended to enhance regulatory T-cell, or Treg, function in neurodegenerative disorders. Company news centers on COYA 302, including clinical and regulatory updates in amyotrophic lateral sclerosis and frontotemporal dementia, biomarker publications, and research on systemic inflammation, lipid peroxidation, axonal injury, and Treg dysfunction.
Coya updates also cover its Treg-focused therapeutic platforms, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Recurring business developments include collaboration activity with Dr. Reddy’s Laboratories, milestone-related revenue disclosures, operating results, stockholder communications, and board or governance changes.
Coya Therapeutics (NASDAQ: COYA) reported encouraging results from a 48-week proof-of-concept study of COYA 302 in four ALS patients. The study found that COYA 302 appears to enhance regulatory T cell function and may slow disease progression, as evidenced by stable ALSFRS-R scores through treatment. Participants initially declining at -1.1 points/month experienced no decline at 24 weeks and only minimal decline at 48 weeks. The treatment was well tolerated with mild side effects and supportive initial efficacy data, indicating a promising direction for larger studies. An IND filing with the FDA is planned for the second half of 2023.
Coya Therapeutics, Inc. (NASDAQ: COYA) has entered into a worldwide agreement with Dr. Reddy’s Laboratories (NYSE: RDY) to develop COYA 302, an investigational combination biologic for neurodegenerative diseases. This product consists of COYA 301 and CTLA4-Ig (Abatacept), targeting chronic inflammation. Coya retains exclusive rights for commercialization in North America, Europe, and Japan, while Dr. Reddy’s can commercialize outside these territories. Coya plans to file an IND in the second half of 2023, aiming for a phase 1b/2 trial in Amyotrophic Lateral Sclerosis (ALS) shortly thereafter. The partnership is expected to enhance Coya’s development efforts.
Coya Therapeutics (NASDAQ: COYA) announced a conference call on March 21, 2023, at 8:00 AM ET, to present clinical data for its investigational biologic COYA 302, targeting Amyotrophic Lateral Sclerosis (ALS). Notably, Coya is conducting a proof-of-concept open-label study to evaluate a dual-mechanism immunotherapy’s safety and efficacy over 12 months. The research combines Interleukin-2 to enhance regulatory T cells and a fusion protein to suppress inflammation. Additionally, Coya will present findings at the 2023 Muscular Dystrophy Association Conference on the same day.
Coya Therapeutics (NASDAQ: COYA) announced results from a proof-of-concept clinical study for its investigational biologic combination, COYA 302, aimed at treating Amyotrophic Lateral Sclerosis (ALS). Conducted over 12 months, the study evaluated safety, tolerability, regulatory T cell function, serum biomarkers, and clinical performance using the ALSFRS-R scale. The dual-mechanism therapy combines low-dose Interleukin-2 and a fusion protein to enhance anti-inflammatory effects while reducing pro-inflammatory responses. Dr. Stanley Appel presented these findings at the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, from March 19 to March 22.
Coya Therapeutics, Inc. (NASDAQ: COYA) has expanded its license agreement with ARScience Biotherapeutics, Inc. to include exclusive worldwide rights for COYA 301, an immunomodulatory cytokine aimed at treating autoimmune and neurodegenerative diseases. This expansion allows Coya to develop COYA 301 as a monotherapy for serious autoimmune diseases in addition to previous rights for neurodegenerative conditions. Coya’s CEO, Howard Berman, emphasizes the potential to address inflammation in a broader patient population. The collaboration aims to advance treatments for conditions characterized by Treg dysfunction and sustained inflammation, leveraging Coya's expertise in Treg-enhancing therapies.
Coya Therapeutics, Inc. (NASDAQ: COYA) has announced plans to present proof-of-concept clinical data from two academic studies on its investigational therapies for Alzheimer’s disease (COYA 301) and Amyotrophic Lateral Sclerosis (ALS) (COYA 302). COYA 301 aims to enhance Treg function in AD patients, with data expected in 1H and 2H 2023. COYA 302 focuses on a biologics combination therapy for ALS, with results to be shared in Q1 2023. Coya, a clinical-stage biotech firm, is leveraging Treg-enhancing therapeutics to address neurodegenerative and autoimmune diseases, emphasizing its commitment to further clinical development.
Coya Therapeutics (NASDAQ: COYA) announced a publication highlighting the potential of expanded human Tregs to suppress neuroinflammation and mitigate Alzheimer's Disease (AD) pathology in a preclinical mice model. The study demonstrated that Treg administration decreased amyloid burden and neuroinflammatory markers, supporting the development of Treg-enhancing therapies as a potential strategy for AD and other neurodegenerative disorders. Coya plans to initiate Phase I clinical trials for these therapies in 2023, with interim data expected by Q1 2024.
Coya Therapeutics, Inc. (Nasdaq: COYA), a clinical-stage biotechnology company, has successfully closed its initial public offering (IPO) of 3,050,000 shares and warrants to purchase additional shares, raising approximately $15.25 million. The shares were sold at $5.00 each, with warrants priced at an exercise fee of $7.50. Trading began on December 29, 2022. Proceeds will primarily support preclinical and clinical trials and various corporate purposes. Underwriters hold an option to purchase 290,000 additional shares to cover over-allotments.
Coya Therapeutics, Inc. (Nasdaq: COYA) announced the pricing of its IPO, offering 3,050,000 shares at $5.00 each, along with warrants to purchase 1,525,000 shares. The IPO is expected to yield approximately $15.25 million in gross proceeds. Net proceeds, after expenses, are projected to be about $13.2 million, intended for advancing clinical trials and corporate purposes. The shares will trade on Nasdaq starting December 29, 2022, and the offering is scheduled to close on January 3, 2023. Joint book-runners include Chardan and Newbridge Securities Corporation.